secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001723128-25-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x
--------------------------------------------------------------------------

- Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).
- Expects to exceed operating cash flow guidance ($280-320M) and capital expenditure guidance ($60-70M).
- Estimates net leverage at approximately 4x as of December 31, 2024.
- Guidance includes 100% of AvKARE EBITDA; adjusted EPS accounts for 35% non-controlling interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000005/0001723128-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000005/amrx-20250115.htm
  HTML page:      https://secwatch.observer/filing/0001723128-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer